What is the Historical Analysis of the Eylea Market Size?
The eylea market has seen considerable growth due to a variety of factors.
• In recent times, the market size of eylea has experienced consistent growth. The market is predicted to expand from a worth of $8.09 billion in 2024 to $8.49 billion in 2025, a compound annual growth rate (CAGR) of 4.9%. Factors influencing growth during the historical period include the prevalence of diabetic macular edema (DME), clinical effectiveness and safety standards, competition from other anti-VEGF treatments, approval for a variety of retinal conditions, and a shift towards intravitreal injections.
What Does Future Hold for The Eylea Market Size Evolve over the Forecast Period?
The Eylea market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations for the eylea market size depict a promising surge in the coming years. The market is set to reach a valuation of $10.75 billion by 2029, experiencing a compound annual growth rate (CAGR) of 6.1%.
The factors contributing to the predicted growth in this period include the advent of novel therapeutic indications, the emergence of biosimilar competition, a higher rate of awareness and diagnosis, tangible real-world evidence, and post-market studies, alongside a patient preference for less frequent injections. Major trends anticipated during this forecast period encompass advancements in imaging technologies, growth in telemedicine and remote monitoring services, patient aid programs, progression in drug delivery technologies, retinal imaging technologies, and clinical trials for new indications.
What Are The Primary Growth Drivers In The Eylea Market?
The Eylea market is anticipated to expand with the escalating incidence of eye ailments. These ocular maladies interfere with the precise functioning of the eye and can negatively influence visual clarity. Often, these issues remain symptomless until reaching a critical stage. Eylea is beneficial in addressing conditions like wet age-related macular degeneration (AMD) and glaucoma, characterized by damage to the retina or macula, impairing vision. The medication prevents the formulation of a protein responsible for creating new, weaker vessels and curtails the swelling of the retina due to blocked blood vessels. For instance, data from a US-based nonprofit, the BrightFocus Foundation, reported in October 2022 that the global count of glaucoma patients was at 80 million, a number projected to surge to over 111 million by 2040. Consequently, the increasing occurrence of eye-related conditions propels the demand and growth in the Eylea market.
What Is The Segmentation Of The Global Eylea Market?
The eylea market covered in this report is segmented –
1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications
Subsegments:
1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes
2) By Vial Package: Single-Dose Vials, Multi-Dose Vials
Pre-Book The Eylea Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Eylea Market Landscape?
The eylea market is seeing a rising trend in research and advancements. The primary focus for dominating industry participants in eylea is the creation of advanced technical solutions. For example, in August 2023, the US-based global biotechnology enterprise, Regeneron Pharmaceuticals, Inc., which develops treatments for grave diseases, got the approval from US FDA for Eylea HD (aflibercept) injection 8 mg. This treatment addresses various diseases such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The dosing routine begins with an initial period of once every four weeks for the first three months across all indications, after which the intervals are adjusted to every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.
Who Are the Key Players In The Eylea Market?
Major companies operating in the eylea market include:
• Regeneron Pharmaceuticals Inc.
• Bayer AG
• Novartis AG
• Roche Holding AG
• Pfizer Inc.
• Amgen Inc.
• Sanofi S.A.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Biogen Inc.
• Alcon Inc.
• Johnson & Johnson
• Eli Lilly and Company
• Genentech Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Samsung Bioepis Co. Ltd.
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Zydus Cadila
• Torrent Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Amneal Pharmaceuticals LLC
• Apotex Inc.
What Are The Regional Insights Into The Eylea Market?
North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
